THE RED SECTIONEfficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel DiseaseGisbert, J P MD, PhD1; Villagrasa, J R MD2; Rodríguez-Nogueiras, A1; Chaparro, M MD, PhD1Author Information 1 Department of Gastroenterology and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain 2 Department of Preventive Medicine, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain Correspondence: Javier P. Gisbert, MD, Playa de Mojácar 29, Urbanización Bonanza, 28669 Boadilla del Monte, Madrid, Spain. E-mail: email@example.com American Journal of Gastroenterology: October 2012 - Volume 107 - Issue 10 - p 1460-1466 doi: 10.1038/ajg.2012.79 Buy Metrics Abstract OBJECTIVES: We assessed the effectiveness of hepatitis B virus (HBV) vaccine in inflammatory bowel disease (IBD) patients, evaluated the impact of immunosuppressors and anti–tumor necrosis factor (anti-TNF) agents, and assessed the effectiveness of revaccination. METHODS: IBD patients were vaccinated against HBV with a quick (0, 1, and 2 months) and double-dose schedule (Engerix B). A second vaccination was administered to nonresponders. RESULTS: Of 241 vaccinated patients, anti-HBs was >10 IU/l in 59% and >100 IU/l in 39%. The response rate (anti-HBs >10 IU/l) was lower among patients under anti-TNF therapy: 46% vs. 62%. In the multivariate analysis, a lower response rate was demonstrated in older patients and those receiving anti-TNFs. The response rate (anti-HBs >100 IU/l) after revaccination was 42%. CONCLUSIONS: The response rate to the HBV vaccination—even with a double-dose schedule—is very low in IBD patients, mainly in those receiving anti-TNFs. However, treatment with immunosuppressors did not affect the efficacy of the vaccine. A considerable—albeit insufficient—success rate may be obtained when two consecutive vaccination courses, each with a three-dose vaccine series, are administered. © The American College of Gastroenterology 2012. All Rights Reserved.